RNXT
RenovoRx, Inc. NASDAQ$0.93
Mkt Cap $32.6M
52w Low $0.70
30.3% of range
52w High $1.45
50d MA $0.94
200d MA $1.02
P/E (TTM)
-2.8x
EV/EBITDA
-1.8x
P/B
5.8x
Debt/Equity
0.0x
ROE
-206.0%
P/FCF
-2.7x
RSI (14)
—
ATR (14)
—
Beta
1.22
50d MA
$0.94
200d MA
$1.02
Avg Volume
333.0K
About
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Al…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.08 | -0.08 | +0.0% | 1.07 | +1.9% | -5.6% | -9.3% | -8.4% | -12.9% | -15.9% | — |
| Nov 13, 2025 | AMC | -0.08 | -0.08 | +0.0% | 0.97 | -8.7% | -23.0% | -17.5% | -19.7% | -24.8% | -20.1% | — |
| Aug 14, 2025 | AMC | -0.08 | -0.08 | +0.0% | 1.24 | -19.4% | -22.9% | -24.2% | -25.7% | -29.8% | -28.0% | — |
| May 15, 2025 | AMC | -0.08 | -0.08 | +0.0% | 1.11 | +0.0% | +6.3% | +11.7% | +9.9% | +9.9% | +10.8% | — |
| Mar 31, 2025 | AMC | -0.13 | -0.12 | +7.7% | 0.99 | -1.0% | -3.0% | +1.0% | -8.1% | -11.0% | -20.2% | — |
| Nov 13, 2024 | AMC | -0.12 | -0.10 | +16.7% | 1.09 | +3.7% | +0.0% | +0.0% | -1.8% | +1.8% | +9.2% | — |
| Aug 13, 2024 | AMC | -0.10 | -0.10 | +0.0% | 1.16 | +1.7% | -3.4% | -4.3% | +1.7% | -8.6% | -8.6% | — |
| May 10, 2024 | AMC | -0.14 | -0.07 | +50.0% | 1.45 | -5.5% | -2.8% | +0.0% | -4.1% | +0.7% | -5.5% | — |
| Apr 1, 2024 | AMC | -0.30 | -0.17 | +43.3% | 1.32 | -0.8% | -6.1% | -4.5% | -9.1% | -12.1% | -11.4% | — |
| Nov 13, 2023 | AMC | -0.30 | -0.27 | +10.0% | 1.05 | +6.3% | -28.3% | -29.2% | -40.4% | -42.9% | -42.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.94 | $0.92 | -2.0% | +4.2% | +4.9% | +8.6% | +9.7% | +8.6% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.95 | +5.6% | +4.3% | +8.7% | +9.5% | +13.3% | +14.4% |
| Feb 17 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.93 | $0.98 | +4.9% | +5.0% | +7.1% | +0.8% | -2.2% | -3.4% |
| Nov 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.78 | $0.79 | +1.7% | +2.2% | +0.9% | +11.2% | +13.8% | +17.9% |
| Aug 25 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.94 | $0.94 | -0.0% | -4.5% | -1.8% | -1.7% | +0.8% | +2.1% |
| Jun 5 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | +0.7% | +0.0% | -1.4% | -3.6% | -2.2% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.18 | $1.24 | +5.1% | +5.1% | +3.4% | +3.4% | +4.2% | +0.8% |
| Apr 28 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.99 | $0.98 | -1.0% | -1.8% | -2.0% | -3.0% | +0.0% | +1.0% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.91 | $0.92 | +1.2% | -3.1% | -13.2% | -12.1% | -8.8% | -13.1% |
| Dec 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.43 | $1.41 | -1.4% | -4.2% | -1.4% | -7.7% | -10.5% | -12.6% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
RenovoRx's modest $1.1M first-year revenue and $13M cash position suggest extended cash burn ahead, making dilution likely before Phase III trial completion in 2027, warranting caution on near-term shareholder returns.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
RNXT's CEO departure effective February 27, 2026 creates leadership uncertainty that could pressure the stock until a successor is named and their strategic vision is clarified.
Mar 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
RNXT's equity issuance will dilute existing shareholders' ownership stakes and may pressure stock price unless proceeds fund high-return growth initiatives.
Mar 23
8-K · 5.02
!!! Very High
RenovoRx, Inc. -- 8-K 5.02: Executive Change
RenovoRx appointed Mark Voll as CFO while he simultaneously resigned as a director, signaling a potential leadership restructuring that investors should monitor for strategic implications.
Feb 6
Data updated apr 26, 2026 11:17pm
· Source: massive.com